[go: up one dir, main page]

AU2001211944A1 - Method of producing adenoviral vector stocks - Google Patents

Method of producing adenoviral vector stocks

Info

Publication number
AU2001211944A1
AU2001211944A1 AU2001211944A AU1194401A AU2001211944A1 AU 2001211944 A1 AU2001211944 A1 AU 2001211944A1 AU 2001211944 A AU2001211944 A AU 2001211944A AU 1194401 A AU1194401 A AU 1194401A AU 2001211944 A1 AU2001211944 A1 AU 2001211944A1
Authority
AU
Australia
Prior art keywords
cells
culture
medium
adenoviral vector
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001211944A
Inventor
Shoupeng Lai
Lee-Cheng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of AU2001211944A1 publication Critical patent/AU2001211944A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polarising Elements (AREA)

Abstract

The present invention provides a method of producing an adenoviral vector stock by providing a culture of cells permissive for growth of adenoviral vectors, wherein the cells are in a medium, culturing the culture under conditions to permit growth of the cells, perfusing fresh medium through the culture for a period of about 1-6 hours, in an amount of at least about two times the volume of medium in the culture, while the density of the cells in the medium is about 40-70% of the density of cells obtained in the medium when the growth of the culture is in the stationary phase, contacting the culture with adenoviral vectors under conditions permissive for the infection of the cells after the perfusion of fresh medium is substantially completed, culturing the infected cells to replicate the adenoviral vectors, and harvesting the infected cells to obtain an adenoviral vector stock.
AU2001211944A 2000-04-07 2000-10-10 Method of producing adenoviral vector stocks Abandoned AU2001211944A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09545385 2000-04-07
US09/545,385 US6168941B1 (en) 2000-04-07 2000-04-07 Method of producing adenoviral vector stocks
PCT/US2000/027946 WO2001077304A1 (en) 2000-04-07 2000-10-10 Method of producing adenoviral vector stocks

Publications (1)

Publication Number Publication Date
AU2001211944A1 true AU2001211944A1 (en) 2001-10-23

Family

ID=24175996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001211944A Abandoned AU2001211944A1 (en) 2000-04-07 2000-10-10 Method of producing adenoviral vector stocks

Country Status (10)

Country Link
US (1) US6168941B1 (en)
EP (1) EP1268748B1 (en)
JP (1) JP4662525B2 (en)
AT (1) ATE384784T1 (en)
AU (1) AU2001211944A1 (en)
CA (1) CA2400746A1 (en)
DE (1) DE60037911T2 (en)
DK (1) DK1268748T3 (en)
ES (1) ES2296653T3 (en)
WO (1) WO2001077304A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
US6591543B2 (en) * 2000-04-14 2003-07-15 Kenneth P. Sabine Top water lure with highly active propeller
US20030087438A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. E1-revertant-free adenoviral composition
WO2003039459A2 (en) * 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
AU2002355058A1 (en) * 2001-11-29 2003-06-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing substance
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
EP1567198A4 (en) * 2002-12-02 2006-05-31 Genvec Inc Materials and methods for treating ocular-related disorders
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US20040229335A1 (en) 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
ES2391975T3 (en) * 2003-07-25 2012-12-03 Genvec, Inc. Adenoviral vector based vaccines
JP2007511507A (en) * 2003-11-14 2007-05-10 ジェンベク、インコーポレイティッド Therapeutic regimen for treating cancer
US20050153419A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing cell lines stable in serum-free medium suspension culture
ES2329607T3 (en) * 2004-02-23 2009-11-27 Crucell Holland B.V. VIRUS PURIFICATION METHODS
CN104593277A (en) * 2004-03-05 2015-05-06 帝斯曼知识产权资产管理有限公司 Process for cell culturing by continuous perfusion and alternating tangential flow
US20050260180A1 (en) * 2004-03-12 2005-11-24 Genvec, Inc. Materials and methods for treating vascular leakage in the eye
EP1737885A2 (en) 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US20060188481A1 (en) * 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
EA015584B1 (en) 2005-03-23 2011-10-31 Генмаб А/С ANTIBODY TO CD38 PERSON AND ITS APPLICATION
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
US8450055B2 (en) 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
BRPI0618441B8 (en) * 2005-11-10 2021-07-27 Genvec Inc adenoviral vector
PT2634243T (en) 2006-07-14 2017-12-18 Patheon Holdings I B V METHOD FOR IMPROVING CELL CULTURE
DK2222697T3 (en) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
PL2235197T3 (en) * 2007-12-27 2018-01-31 Baxalta GmbH Cell culture processes
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011086509A1 (en) * 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
WO2013012771A2 (en) * 2011-07-19 2013-01-24 Wenlin Huang Clinical applications of a recombinant human endostatin adenovirus (e10a) injection
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
TWI710635B (en) 2014-10-09 2020-11-21 美商珍維克公司 Adenoviral vector encoding human atonal homolog-1 (hath1)
KR20190104194A (en) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. Patterned Administration of Immunosuppressants Coupled to Synthetic Nanocarriers
JP7323512B2 (en) * 2017-10-06 2023-08-08 ロンザ リミテッド Automated control of cell culture using Raman spectroscopy
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2020223205A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
US20200390718A1 (en) 2019-05-28 2020-12-17 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117881A (en) 1977-06-14 1978-10-03 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration System for and method of freezing biological tissue
US4327799A (en) 1979-06-18 1982-05-04 Helmholtz-Institut Fur Biomedizinische Technik Process and apparatus for freezing living cells
US4304293A (en) 1979-06-18 1981-12-08 Helmholtz-Institut Fur Biomedizinische Technik Process and apparatus for freezing living cells
US4377077A (en) 1981-07-15 1983-03-22 Biotech Research Laboratories, Inc. Device and method for controlled freezing of cell cultures
US4455842A (en) 1981-07-15 1984-06-26 Biotech Research Laboratories, Inc. Device and method for controlled freezing of cell cultures
US4676070A (en) 1984-11-30 1987-06-30 The Board Of Regents, The University Of Texas Apparatus and method for cryopreparing biological tissue
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
AU732703B2 (en) * 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process

Also Published As

Publication number Publication date
DE60037911D1 (en) 2008-03-13
ES2296653T3 (en) 2008-05-01
WO2001077304A1 (en) 2001-10-18
DE60037911T2 (en) 2009-01-08
CA2400746A1 (en) 2001-10-18
JP2003530104A (en) 2003-10-14
DK1268748T3 (en) 2008-06-02
ATE384784T1 (en) 2008-02-15
US6168941B1 (en) 2001-01-02
JP4662525B2 (en) 2011-03-30
EP1268748A1 (en) 2003-01-02
EP1268748B1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
AU2001211944A1 (en) Method of producing adenoviral vector stocks
AU2003207399A1 (en) Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood, and differentiation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues
CA2390281A1 (en) Hematopoietic differentiation of human embryonic stem cells
AU2934197A (en) Isolation, propagation, and directed differentiation of stem cells from central nervous system of mammals
EP1360314A4 (en) Chemically defined medium for cultured mammalian cells
WO2003038076A1 (en) Immortalized mesenchymal cells and utilization thereof
CA2407505A1 (en) Hepatocyte lineage cells derived from pluripotent stem cells
AU7567501A (en) Cartilage replacement and methods for the production thereof
NO20006096D0 (en) Medium for culturing animal cells and method for producing protein using the same
WO2006047380A3 (en) Method and media for single cell serum-fee culture of cho cells
CA2410931A1 (en) Mammalian gamete and embryo culture media supplement and method of using same
ATE510004T1 (en) IN VITRO TECHNIQUES FOR USE WITH STEM CELLS
DK1200561T3 (en) Recombinant stable cell clone, its preparation and use
CA3168116A1 (en) Utilization of fgf activators in culture media
WO2002050251A3 (en) A device and method for seed-train expansion of mammalian cells
WO2004043401A3 (en) Method of preparing anti-angiogenic drug from cartillage and chondrocytes and methods of use
EP1096017A3 (en) Method for increasing the production of physiologically active substances by cultured cells
CN107034185A (en) A kind of primary isolated culture method of naked mole mesenchymal stem cells MSCs
CA2530318A1 (en) Method of storing and/or transporting in vitro cell cultures
NO20006545D0 (en) Method for in vitro maturation of human germ cells
DK1651754T3 (en) Myeloma cell culture in transferrin-free medium with low iron content
AU2182801A (en) Method for producing adherent animal cells
WO2002016584A3 (en) Process for the preparation of neutrophil inhibitory factor
CN106479959A (en) A kind of construction method of paddlefish heart cell system
SU865245A1 (en) Method of preserving cells tissues of plants